The program includes vaccine scale-up and manufacturing by SK bioscience with the company’s CDMO subsidiary, IDT Biologika, responsible for fill-finish operations.

The expanded agreement adds six commercial biologics programs at the CDMO’s Denmark facility to five already assigned to its site in Japan.

The site has finished its first Good Manufacturing Practice batches of drug substance and drug product, advancing its overseas production operations.

The agreement gives Fresenius exclusive access to candidates across 13 therapeutic areas, with development planned over the next decade.

The 44,500-square-meter facility will manufacture cell culture media, process liquids, and sterile sampling products for Asia-Pacific customers.

The capital project will add 160,000 liters of manufacturing capacity, increasing the total capacity by approximately 25% to nearly one million liters.

The European Medicines Agency inspection supports renewal of GMP certificate at pharmaceutical analytical testing and development site.

The expansion in Visp will now include three multiproduct suites, with commercial manufacturing capacity expected to be operational from 2028.